blood cancer

AstraZeneca Plc (NASDAQ:AZN) released data from the ECHO Phase 3 trial of Calquence (acalabrutinib) plus bendamustine and rituximab compared to standard-of-care chemoimmunotherapy (bendamustine and rituximab) in adult patients at or over 65 years of age (n=635) with previously untreated...

House Majority Leader Steve Scalise has been diagnosed with a treatable form of blood cancer, known as multiple myeloma, CNBC reported. Scalise disclosed that he had started medical treatment after feeling unwell for some time. The treatment is expected to last several months....

Gilead Sciences Inc (NASDAQ: GILD) recently notified the FDA of its decision to voluntarily withdraw the use of Zydelig for two types of blood cancer, including follicular lymphoma (FL) and small lymphocytic leukemia (SLL). In 2014, the FDA granted accelerated approval to treat...

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced topline data from the Phase 3 PANTHER study evaluating pevonedistat in blood cancer indications. The trial did not achieve the pre-defined statistical significance for the primary endpoint of event-free survival (EFS). Patients were...

Pfizer Inc (NYSE: PFE) has agreed to acquire Trillium Therapeutics Inc (NASDAQ: TRIL) for $18.50 per share, equivalent to an implied equity value of $2.26 billion. The offer price represents a 118% premium to the 60-day weighted average price for Trillium. Trillium's...

BeiGene Ltd (NASDAQ: BGNE) announced positive topline results from an interim analysis of the Phase 3 SEQUOIA trial comparing Brukinsa (zanubrutinib) to bendamustine and rituximab (B+R). The trial included patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or...

The FDA has instituted a clinical hold on Magenta Therapeutics Inc's (NASDAQ: MGTA) Investigational New Drug Application (IND) of MGTA-117. In June, the IND was filed to initiate a Phase 1/2 trial of MGTA-117 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS...

In a filing with SEC on Thursday, Caribou Biosciences (NASDAQ: CRBU) is penciling in a $100 million initial public offering. The firm expects that its new shares will trade on the NASDAQ under the symbol "CRBU" once the IPO closes.  BofA Securities, Citigroup, and SVB...

Precision BioSciences Inc (NASDAQ: DTIL) has dosed the first patient in its Phase 1 trial with PBCAR19B in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) PBCAR19B is an immune-evading allogeneic CAR T stealth cell candidate. The study's primary objective is...

The FDA has approved Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in pediatric and adult patients. The approval covers the use of Rylaze as a...

Salarius Pharmaceuticals Inc (NASDAQ: SLRX) has initiated an investigator-initiated Phase 1/2 trial to investigate seclidemstat as a potential treatment for hematologic cancers. The trial will be an open-label, dose-finding, dose-expansion study to determine the maximum tolerated...

Protagonist Therapeutics Inc (NASDAQ: PTGX) has announced updated results from the ongoing Phase 2 study of rusfertide for polycythemia vera (PV), a type of blood cancer. Data were presented at the European Hematology Association 2021 Virtual Congress. Rusfertide demonstrated long-...

Curis Inc (NASDAQ: CRIS) has announced updated data from its ongoing Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Key findings were presented at the European Hematology Association 2021 Virtual Congress and...

Allogene Therapeutics Inc (NASDAQ: ALLO) has announced a fresh set of data from its AlloCAR T program in the lead-up to the American Society of Clinical Oncology Annual Meeting. It includes data from Phase 1 ALPHA (ALLO-501) and ALPHA2 (ALLO-501A) trials in relapsed/refractory...

BeiGene Ltd (NASDAQ: BGNE) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing Brukinsa (zanubrutinib) against Johnson & Johnson's (NYSE: JNJ) Imbruvica (ibrutinib) in adults with relapsed or refractory chronic...